HC Wainwright Has Positive Estimate for ETON Q3 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - HC Wainwright increased their Q3 2025 earnings per share estimates for Eton Pharmaceuticals in a research note issued on Thursday, May 29th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.14 for the quarter, up from their prior forecast of $0.13. HC Wainwright has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals' Q4 2025 earnings at $0.22 EPS, Q1 2026 earnings at $0.32 EPS, Q2 2026 earnings at $0.39 EPS, Q3 2026 earnings at $0.46 EPS and Q4 2026 earnings at $0.50 EPS.

A number of other equities analysts also recently issued reports on the company. Craig Hallum increased their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. B. Riley reiterated a "buy" rating and issued a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th.

Eton Pharmaceuticals Trading Down 0.1%

ETON traded down $0.02 during trading on Friday, reaching $18.90. The stock had a trading volume of 428,570 shares, compared to its average volume of 204,827. The stock's 50 day moving average is $15.81 and its two-hundred day moving average is $14.67. The company has a market capitalization of $506.86 million, a price-to-earnings ratio of -85.91 and a beta of 1.22. Eton Pharmaceuticals has a one year low of $3.18 and a one year high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Eton Pharmaceuticals by 18.3% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after acquiring an additional 1,634 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Eton Pharmaceuticals by 29.6% in the fourth quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock worth $195,000 after acquiring an additional 3,351 shares during the last quarter. AlphaQuest LLC purchased a new stake in shares of Eton Pharmaceuticals in the first quarter worth $53,000. Tower Research Capital LLC TRC purchased a new stake in shares of Eton Pharmaceuticals in the fourth quarter worth $86,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Eton Pharmaceuticals in the first quarter worth $101,000. Institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.